Related Experiment Video

Updated: Apr 23, 2026

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology
05:21

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology

Published on: May 16, 2022

2.6K

A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery

Weikang Xu1, Xinmiao Wei1, Kun Wei1

  • 1School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China; National Engineering Research Center for Tissue Restoration and Reconstruction, Guangzhou 510006, China; Guangdong Province Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou 510006, China.

International Journal of Pharmaceutics
|October 2, 2014
PubMed

Insights

This study developed a novel drug delivery system using mesoporous silica and PLGA microspheres for controlled release of anti-tuberculosis drugs rifampicin and isoniazid. The system significantly prolongs drug release, offering potential for treating bone tuberculosis.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Pharmaceutical Sciences

Background:

  • Tuberculosis (TB) treatment requires effective drug delivery systems.
  • Controlling the release of anti-TB drugs like rifampicin (RIF) and isoniazid (INH) is crucial for efficacy.
  • Existing drug delivery methods may have limitations in sustained release.

Purpose of the Study:

  • To fabricate and evaluate a multi-component drug delivery system for controlled release of RIF and INH.
  • To investigate the release kinetics of RIF and INH from mesoporous silica (MS) incorporated into poly-(DL-lactic-co-glycolic) acid (PLGA) microspheres (MS/PLGA).
  • To assess the cytotoxicity of the developed MS/PLGA system.

Main Methods:

  • Fabrication of drug-laden mesoporous silica (MS) particles.
  • Incorporation of drug-laden MS into poly-(DL-lactic-co-glycolic) acid (PLGA) microspheres to create a multi-component system (MS/PLGA).
  • In vitro drug release studies for RIF and INH from MS, PLGA, and MS/PLGA systems.
  • Cytotoxicity assessment using CCK-8 assay.

Main Results:

  • The MS/PLGA system significantly prolonged the release of both RIF and INH compared to single-component systems (MS or PLGA alone).
  • Drug-laden MS showed rapid release (100% INH in 15h, 70% RIF in 50h).
  • Drug-laden PLGA showed slower release (100% INH/RIF in 30/40 days).
  • MS/PLGA exhibited sustained release, with only ~48% RIF and ~57% INH released after 60 days.
  • CCK-8 assay confirmed the MS/PLGA system exhibited no cytotoxicity.

Conclusions:

  • The developed MS/PLGA multi-component system offers a promising approach for sustained and controlled delivery of anti-TB drugs RIF and INH.
  • This system demonstrates significantly improved drug release profiles compared to conventional MS and PLGA systems.
  • The long-term release capability of this MS/PLGA system opens new therapeutic avenues for challenging conditions like bone tuberculosis.
Keywords:
IsoniazidMesoporous silicaPLGAProlong releaseRifampicin

More Related Videos

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

11.0K
Designing Porous Silicon Films as Carriers of Nerve Growth Factor10:12

Designing Porous Silicon Films as Carriers of Nerve Growth Factor

Published on: January 25, 2019

12.0K

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
148
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
199
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
970
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
288
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
167
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
127